

**May 12,2022**

**Supplementary Documents of  
Consolidated Financial Results for  
the Year Ended in March 31, 2022 (FY2021)**



**Stock code : 4886 (TSE)**

**ASKA Pharmaceutical Holdings Co., Ltd.**

# Statements of Income (Consolidated)

(Millions of yen)	*FY2020 Apr - Mar Actual	FY2021 Apr - Mar Actual	Actual +/-	Growth +/-
Net sales	55,181	56,607	1,426	2.6%
Operating profit	3,609	4,795	1,186	32.9%
Ordinary profit	3,092	4,880	1,788	57.8%
Profit attributable to owners of parent	2,713	4,290	1,576	58.1%

## Factors for increase in sales and profit

- ✓ Pharmaceutical drugs business showed favorable performance due to factors such as growth in sales of obstetrics and gynecology products “RELUMINA” and “FREWELL” as well as sales of internal medicine products “THYRADIN” and “RIFXIMA”. Furthermore, “CANDESARTAN” and “LEUPRORELIN” exceeded the sales forecast due to alternative demand spurred by problems in competitors’ supplies.
- ✓ Sales results for drugs for livestock and companion animals and feed additives in the animal health drugs business performed well
- ✓ Although there were extraordinary losses, including impairment of intangible assets due to suspension of development of CDB-2914 (Ulipristal), net income increased due to a gain on sales of fixed assets resulting from the transfer of land and buildings owned by ASKA Pharmaceutical Co., Ltd.

\*The figures announced as ASKA Pharmaceutical Co., Ltd.

# Net Sales by Business (Consolidated)

(Millions of yen)	*FY2020 Apr - Mar Actual	FY2021 Apr - Mar Actual	Breakdown	Actual +/-	Growth +/-
Pharmaceutical drugs	50,314	50,791	89.7%	477	0.9%
Animal health drugs	4,742	5,630	9.9%	888	18.7%
Others	125	185	0.3%	61	48.4%
<b>Total</b>	<b>55,181</b>	<b>56,607</b>	<b>100.0%</b>	<b>1,426</b>	<b>2.6%</b>

\*The figures announced as ASKA Pharmaceutical Co., Ltd.

# FY2022 Forecast (Consolidated)

(Millions of yen)	FY2021 Results	FY2022 Forecast	Actual+/-	% +/-
Net sales	56,607	57,500	892	1.6%
Operating profit	4,795	4,200	- 596	-12.4%
Ordinary profit	4,880	4,300	- 581	-11.9%
Profit attributable to owners of parent	4,290	3,300	- 990	-23.1%

## Factors for increase and decrease

- ✓ Net sales is projected to increase thanks to growth in pharmaceutical drugs business centered on brand-name drugs such as “RELUMINA”, “RIFXIMA”, “THYRADIN”
- ✓ On the other hand, operating income and ordinary income are expected to decrease due to an increase in R&D expenses and an expected increase in costs accompanying normalization of business activities that had been affected by the new coronavirus infection
- ✓ Net income is expected to decrease due to the absence of extraordinary gains that were recorded in the previous fiscal year

# Sales of main products of ASKA Pharmaceutical Co., Ltd.

(Millions of yen)

Area	Products (generic name)	FY2020 Apr - Mar	FY2021 Apr - Mar		FY2022	
		Actual	Actual	YOY (%)	Forecast	YOY (%)
Internal Medicine	CANDESARTAN <sup>*1, *2</sup> (candesartan)	12,329	12,394	100.5%	10,840	87.5%
	THYRADIN (levothyroxine)	7,209	7,499	104.0%	7,714	102.9%
	RIFXIMA (rifaximin)	4,334	4,854	112.0%	5,289	109.0%
	MERCAZOLE (thiamazole)	1,401	1,458	104.0%	1,440	98.8%
	AMLODIPINE <sup>*1</sup> (amlodipine)	1,294	1,073	82.9%	963	89.7%
Obstetrics Gynecology	RELUMINA (relugolix)	5,709	7,334	128.4%	9,779	133.3%
	FREWELL <sup>*1</sup> (norethindrone/ethinylestradiol)	2,952	3,463	117.3%	3,083	89.0%
	ANGE (levonorgestrel/ethinylestradiol)	908	854	94.1%	896	104.9%
	MAGSENT <sup>*3</sup> (magnesium sulfate)	908	850	93.6%	682	80.2%
	LUTEUM (progesterone)	531	661	124.5%	836	126.5%
Urology	LEUPRORELIN <sup>*1, *4</sup> (leuprorelin)	4,502	5,183	115.1%	4,589	88.5%

\* 1 Generic drugs \* 2 Including combination drugs \* 3 Total value of magnesium sulfate preparation


\* 4 1.88mg formulation is for gynecological indications only, but numerical figure is combined with the 3.75mg formulation

# Sales Proportion of Brand-name Drugs


■ Brand-name drugs

■ Generic drugs

FY2020  
Apr - Mar




FY2021  
Apr - Mar



# R&D Status

## Trend of R&D expenses

(Millions of yen)



As of May 12<sup>th</sup>, 2022

Development code (Generic name) / Indication	Phase
LF111 (drospirenone) Contraception	Ph III
(option agreement) PMS/PMDD	Ph II (IIT*1)
(option agreement) Cervical Dysplasia	Ph I / II (Korea)
TRM-270 Adhesion Barrier	Preparing clinical trial
L-105 (rifaximin) Hepatic encephalopathy (pediatrics)	Ph II / III
AKP-009(ludaterone acetate) Benign Prostatic Hyperplasia	Ph II *2
Relugolix Combination Tablet Uterine Fibroid	Preparing Development

\*1 Investigator-initiated clinical trial

\*2 Additional Ph I trial at a higher dose ended in April 2022.